Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
87 EUR | -0.57% | -3.33% | -.--% |
May. 29 | BofA Securities Adjusts Crane Price Target to $165 From $140, Maintains Buy Rating | MT |
May. 27 | CR Double-Crane Pharmaceutical's Unit Gets Nod for Phloroglucinol Injection | MT |
Sales 2024 * | 2.31B 2.13B | Sales 2025 * | 2.47B 2.28B | Capitalization | 8.52B 7.86B |
---|---|---|---|---|---|
Net income 2024 * | 282M 260M | Net income 2025 * | 332M 306M | EV / Sales 2024 * | 3.68 x |
Net cash position 2024 * | 37.28M 34.37M | Net cash position 2025 * | 376M 347M | EV / Sales 2025 * | 3.3 x |
P/E ratio 2024 * |
30.7
x | P/E ratio 2025 * |
25.9
x | Employees | - |
Yield 2024 * |
0.54% | Yield 2025 * |
0.61% | Free-Float | 85.42% |
Latest transcript on Crane Company
1 week | -3.33% | ||
1 month | -11.22% | ||
3 months | -4.92% | ||
6 months | -8.42% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.44% | 16.15B | |
-21.70% | 11.78B | |
-4.42% | 6.65B | |
+43.07% | 2.08B | |
+10.43% | 1.66B | |
+10.04% | 922M | |
+17.81% | 909M | |
-6.97% | 640M | |
-16.03% | 598M |
- Stock Market
- Equities
- CR Stock
- T12 Stock